Proteomics News and Research

RSS

The term 'proteome' was first coined in 1994, and refers to all the proteins in a cell, tissue, or organism. Proteomics refers to the study of the proteome. Because proteins are involved in almost all biological activities, the proteome is a rich source of biological information.

OSEO awards €10.4 million to DIPPAL project targeting Alzheimer's disease

The biotech companies PHARNEXT and BIOSYSTEMS INTERNATIONAL, the Bordeaux Hospital where CMRR is located, the university Bordeaux Segalen and Inserm (the center U897 "Epidemiology and Biostatistics") have joined forces to carry out the DIPPAL2i project. This innovative research and industrial development project is targeting Alzheimer's disease (AD) and has attracted significant financial support from OSEO (the French state innovation agency).

18 Nov 2010

New technique to identify cancer biomarkers

The University of Liège has presented TARGETOME, the most recent of its spin-offs, which is also the first to spring from its applied geno-proteomics centre, GIGA.

18 Nov 2010

Myrexis presents data on MPC-9528 cancer metabolism inhibitor at EORTC/NCI/AACR Symposium

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented two posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics," in Berlin, Germany.

18 Nov 2010

New pharmacogenetic test enables a personalized medicine approach

Luminex Corporation, today announced that it has commercially launched its first pharmacogenetic test, the xTAG CYP2D6 Kit, which recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

From Luminex 17 Nov 2010

ICON, Proteome enter alliance to provide expanded biomarker solutions

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and Proteome Sciences a leading provider of protein biomarker discovery, validation, and assay development services, today announced the formation of a strategic alliance to provide pharmaceutical companies with an expanded biomarker solution to allow earlier assessments in the development of new medicines.

15 Nov 2010

UC researchers receive four-year grant to study mechanism of malarial parasite replication in RBCs

Today, about half the world's population lives in areas at risk of malaria transmission. The disease is transmitted to humans through bites from mosquitoes, and each year causes hundreds of thousands of deaths worldwide, with about 1,500 of these in the United States.

8 Nov 2010

Onconome receives $231,000 cash grant under QTDP program

Onconome, Inc. announced today that it was awarded a cash grant totaling approximately $231,000 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP was enacted as part of the Patient Protection and Affordable Care Act of 2010.

7 Nov 2010

ArcticDx develops test to determine inherited risk for AMD

Established in 2007 and based in Toronto, ArcticDx has developed a test, Macula Risk-, the first of its kind and specifically designed to determine one's inherited risk for age-related macular degeneration (AMD), the most common form of acquired blindness in the developed world, affecting over 10% of individuals. ArcticDx will use the PBDF investment to undertake studies in support of a planned filing for Food and Drug Administration (FDA) approval for Macula Risk.

2 Nov 2010

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Caliper Life Sciences, Inc., today reported results for its third quarter ended September 30, 2010. Third quarter GAAP revenue decreased 8% to $29.7 million from $32.2 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 10% on a reported basis and 11% on an organic basis.

28 Oct 2010

New findings suggest way to treat lung diseases

A new study of an exotic, infectious virus that has caused three recent outbreaks in the United States reveals clues to how the virus might damage lungs during infection. The findings also suggest possible new ways to treat lung diseases in humans.

28 Oct 2010

New G-DOC repository for biological information

Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center, announces the launch of the Georgetown Database of Cancer or G-DOC. Under development for two years, G-DOC is a repository for biological information that is normally only available in scattered information libraries and tissue banks, if at all. Data sets grow as researchers deposit new information. G-DOC also contains relevant tools to analyze the data, plus new ones not seen before.

27 Oct 2010

Human haptoglobin gene mutation increases risk of diabetic complications

Type 1 diabetes (T1D), formerly known as juvenile diabetes, is a multifactorial disease of complex etiology characterized by the autoimmune destruction of pancreatic beta cells. In addition to genetic susceptibility, it is generally accepted that environmental factors play important roles in triggering disease, with virus infection having perhaps the strongest association.

27 Oct 2010

New feature on SciVerse ScienceDirect presents proteins in three dimensions

Elsevier, a world-leading publisher of scientific, medical and technical products and services, introduces Protein Viewer, a new, interactive feature on SciVerse ScienceDirect for the Journal of Molecular Biology (JMB). With Protein Viewer, readers of JMB now have the power to expand and rotate molecules within the actual article. SciVerse ScienceDirect merges features of the World Protein Database and Jmol, and embeds them into the article, making its use more convenient and user-friendly.

26 Oct 2010

First in vivo screening system for complete human nuclear hormone receptor family

The InDanio screening system can be used, for example, to functionally characterize 'orphan' receptors - those for which their natural ligands or specific function are unknown - and thus qualify them as potential targets for drug discovery. The system can also be used to screen compound libraries in order to identify and refine potential new drugs that target NR proteins.

20 Oct 2010

Study reveals how cells crank up cancer activators

A new technique that searches blood for the tiniest remnants of broken down proteins has revealed new information about how cells crank up cancer activators called proteases. The results improve researchers' understanding of the mechanics of breast cancer and point to where to look for possible indicators of early disease.

20 Oct 2010

Gene Biodesign joins Roche NimbleGen Certified Service Provider Program

Roche NimbleGen announced today that Taipei-based genomic services provider Gene Biodesign Enterprises Co. has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program.

13 Oct 2010

Tecan, Luminex collaborate to develop automated newborn screening solution

The Tecan Group and Luminex Corporation have announced that they will collaborate on the development of a new automated newborn screening solution that will provide faster results for infants' potential health concerns.

From Tecan 13 Oct 2010

QIAGEN, Abbott enter agreement to strengthen testing menus for automated in-vitro diagnostic applications

QIAGEN and Abbott today announced that they have entered into an agreement that significantly strengthens both companies' testing menus for automated in-vitro diagnostic applications in the United States and Canada. Financial terms were not disclosed.

From QIAGEN Manchester Limited 13 Oct 2010

GeneGo integrates SDM platform with MetaCore and MetaDrug

GeneGo, Inc., a leading provider of databases, software and services in systems biology and chemistry, announced today that they have integrated GenomeQuest's Sequence Data Management (SDM) platform with GeneGo's MetaCore and MetaDrug.

8 Oct 2010

Gentel Biosciences, RayBiotech to develop antibody array products with APiX chromogenic detection platform

Gentel Biosciences, a leader in proteomics profiling tools and RayBiotech, Inc., a pioneer and leader in protein and antibody array technologies, jointly announce today their partnership to develop and market RayBiotech's vast collection of antibody array products covering a wide variety of cytokines and other proteins for use with Gentel's APiX chromogenic detection platform.

5 Oct 2010